Non-thyroidal second primary malignancy in papillary thyroid cancer patients

被引:4
作者
Duarte, Diana Borges [1 ]
Silva, Vania Benido [1 ]
Assuncao, Guilherme [1 ]
Carvalho, Andre Couto [1 ]
Freitas, Claudia [1 ]
机构
[1] Ctr Hosp & Univ Porto, Div Endocrinol, Porto, Portugal
关键词
thyroid cancer; papillary thyroid cancer; second primary malignancy; radioiodine therapy; RADIOACTIVE IODINE; I-131; TREATMENT; ADULT PATIENTS; INCREASED RISK; PRIMARY TUMORS; CARCINOMA; ASSOCIATION; NATIONWIDE;
D O I
10.1530/ETJ-22-0018
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionThe occurrence of non-thyroidal second primary malignancy (NTSPM) in patients with papillary thyroid cancer (PTC) is well documented, but epidemiological data are conflicting. Objective: The aim of this study was to evaluate the incidence of NTSPM in a large series of patients with PTC and to assess its potential risk factors. Methods: Single-center cohort study with retrospective data collection conducted on consecutive PTC patients diagnosed from 1988 to 2018 with a minimum follow-up time of 2 years. NTSPM was defined as any primary malignancy with histological confirmation occurring in an anatomical site other than the thyroid. According to the timing of occurrence, NTSPM were subdivided into anachronous, synchronous or metachronous (diagnosed > 6 months before, within 6 months and > 6 months after PTC diagnosis, respectively). Results: We included 773 individuals (83.3% females), median age at PTC diagnosis was 47.0 (IQR: 37.0-58.0) years and median follow-up time was 9.9 (6.2-16.3) years. Incidence of NTSPM was 15.5% (n = 120) and its standard incidence ratio (SIR) was higher when compared to the general population (SIR: 2.70). Family history of malignancy and younger age at diagnosis were associated respectively with 206 and 4% increased risk of developing metachronous neoplasia (HR: 2.06 (95% CI: 1.10-3.86) and 1.04 (95% CI: 1.02-1.05), respectively). Conclusion: In our series, the occurrence of NTSPM was not uncommon and its incidence was higher compared to the general population. First-degree family history of malignancy was a strong risk factor for multiple primary malignancies.
引用
收藏
页数:10
相关论文
共 50 条
[41]   Investigation of Second Primary Lung Malignancy Rates in Laryngeal Cancer Patients [J].
Hatipoglu, Esra Bozkurt ;
Saylam, Guleser ;
Bayir, Omer ;
Karahan, Sevilay ;
Han, Unsal ;
Korkmaz, Mehmet Hakan .
B-ENT, 2024, 20 (04) :220-225
[42]   Increased Risk of Second Primary Malignancy in Pediatric and Young Adult Patients Treated with Radioactive Iodine for Differentiated Thyroid Cancer [J].
Marti, Jennifer L. ;
Jain, Kunal S. ;
Morris, Luc G. T. .
THYROID, 2015, 25 (06) :681-687
[43]   Non-thyroidal disease syndrome in patients with systemic lupus erythematosus: relation to disease inflammatory activity [J].
Xue Meng ;
Ang Lv ;
Mulin Tang ;
Xue Liu ;
Xinhui Wang ;
Yuchen Li ;
Yuwei Chai ;
Qingqing Yang ;
Chunjia Kou ;
Li Zhang ;
Ming Li ;
Haiqing Zhang .
Clinical Rheumatology, 2024, 43 :1551-1558
[44]   Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma [J].
Lang, Brian Hung-Hin ;
Lo, Chung-Yau ;
Wong, Irene Oi Ling ;
Cowling, Benjamin J. .
SURGERY, 2010, 148 (06) :1191-1196
[45]   Deciphering the Risk of Developing Second Primary Thyroid Cancer Following a Primary Malignancy-Who Is at the Greatest Risk? [J].
Trinh, Lily N. ;
Crawford, Andrew R. ;
Hussein, Mohammad H. ;
Zerfaoui, Mourad ;
Toraih, Eman A. ;
Randolph, Gregory W. ;
Kandil, Emad .
CANCERS, 2021, 13 (06) :1-14
[46]   Survival for endometrial cancer as a second primary malignancy [J].
Medina, Heidy N. ;
Schlumbrecht, Matthew P. ;
Penedo, Frank J. ;
Pinheiro, Paulo S. .
CANCER MEDICINE, 2022, 11 (06) :1490-1501
[47]   Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer [J].
Kim, Kyeong Jin ;
Kim, Kyoung Jin ;
Choi, Jimi ;
Kim, Nam Hoon ;
Kim, Sin Gon .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2023, 115 (06) :695-702
[48]   Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysis [J].
Sawka, Anna M. ;
Thabane, Lehana ;
Parlea, Luciana ;
Ibrahim-Zada, Irada ;
Tsang, Richard W. ;
Brierley, James D. ;
Straus, Sharon ;
Ezzat, Shereen ;
Goldstein, David P. .
THYROID, 2009, 19 (05) :451-457
[49]   Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer [J].
Tobias, Balint ;
Halaszlaki, Csaba ;
Balla, Bernadett ;
Kosa, Janos P. ;
Arvai, Kristof ;
Horvath, Peter ;
Takacs, Istvan ;
Nagy, Zsolt ;
Horvath, Evelin ;
Horanyi, Janos ;
Jaray, Balazs ;
Szekely, Eszter ;
Szekely, Tamas ;
Gyori, Gabriella ;
Putz, Zsuzsanna ;
Dank, Magdolna ;
Valkusz, Zsuzsanna ;
Vasas, Bela ;
Ivanyi, Bela ;
Lakatos, Peter .
PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (01) :27-33
[50]   Increased thyroid malignancy in patients with primary hyperparathyroidism [J].
Li, Luchuan ;
Li, Baoyuan ;
Lv, Bin ;
Liang, Weili ;
Zhang, Binbin ;
Zeng, Qingdong ;
Turner, Andrew G. ;
Sheng, Lei .
ENDOCRINE CONNECTIONS, 2021, 10 (08) :885-893